How should overall survival be analysed in randomised clinical trials in cancer if participants receive subsequent treatment lines? A stakeholder consultation
This work demonstrates that all stakeholder groups are interested in how subsequent treatment lines may impact overall survival and provides evidence on what future methodological work in the area should consider. The next step of this work will investigate whether it is possible to estimate the overall survival treatment effect in a hypothetical scenario where participants who received second-line therapy all received the same second-line therapy. This will aim to complement the existing treatment policy approach and quantify the impact of subsequent treatments.
Authors
- Peter Wheatstone
- Kara‐Louise Royle (ORCID: https://orcid.org/0000-0003-0225-1199)
- David Allan Cairns (ORCID: https://orcid.org/0000-0002-2338-0179)
- Ian R. White (ORCID: https://orcid.org/0000-0002-6718-7661)
- David Meads (ORCID: https://orcid.org/0000-0003-1369-2483)
- Jennifer K. Visser‐Rogers
Institutions
- University of Leeds (GB)
- Coronado Unified School District (US)
- Leeds Trinity University (GB)
- MRC Clinical Trials Unit at UCL (GB)
- Cancer Research UK Clinical Trials Unit (GB)
- University College London (GB)
Publication Details
- Journal
- Trials
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1186/s13063-025-09148-3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK
- National Institute for Health and Care Research
- Department of Health and Social Care
- Medical Research Council